1. Home
  2. RBB vs GLSI Comparison

RBB vs GLSI Comparison

Compare RBB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RBB Bancorp

RBB

RBB Bancorp

N/A

Current Price

$21.91

Market Cap

375.4M

Sector

Finance

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

N/A

Current Price

$23.03

Market Cap

372.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RBB
GLSI
Founded
2008
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.4M
372.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
RBB
GLSI
Price
$21.91
$23.03
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$22.00
$50.00
AVG Volume (30 Days)
54.4K
244.5K
Earning Date
04-28-2026
01-01-0001
Dividend Yield
2.92%
N/A
EPS Growth
N/A
N/A
EPS
1.24
N/A
Revenue
$5,293,000.00
N/A
Revenue This Year
$15.23
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
$17.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.40
$7.78
52 Week High
$22.69
$34.10

Technical Indicators

Market Signals
Indicator
RBB
GLSI
Relative Strength Index (RSI) 57.23 44.73
Support Level $20.04 $9.47
Resistance Level $22.54 $32.61
Average True Range (ATR) 0.49 2.25
MACD 0.00 -0.95
Stochastic Oscillator 62.32 18.80

Price Performance

Historical Comparison
RBB
GLSI

About RBB RBB Bancorp

RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: